Исполнительный указ президента США Дональда Трампа о психоделиках может ускорить реформу каннабиса
В минувшие выходные президент Дональд Трамп подписал указ, который ускоряет исследования психоделиков, таких как псилоцибин, MDMA и ибогаин.
Atai Life Sciences
Price: 3.80Company and Business Model
Atai Life Sciences is a biotechnology company focused on developing innovative treatments for mental health disorders. Its core products include psychedelic compounds and therapies aimed at addressing conditions such as depression and anxiety. The company operates primarily in the healthcare sector, with major revenue sources stemming from research collaborations, licensing agreements, and potential future product sales.
Investment Profile
The investment profile of Atai Life Sciences is more aligned with growth investors, given its focus on developing novel therapies and the potential for significant market impact. However, the company's current financial performance indicates higher risk, making it less suitable for conservative investors seeking stable returns. The stock may appeal to those with a medium to long-term investment horizon, as it navigates the complexities of drug development and regulatory approval.
Fundamental metrics (experimental)
- EPS (TTM) — earnings per share for the last 12 months, $
- -3.00 Risk
- Revenue QoQ — quarter-over-quarter revenue growth
- -10.5% ↓
- EPS surprise
- 27.3% better than expected
- 20d volatility
- 4.3% stable
FMP / FinFeed data updated:
2026-06-09
Reco: Sell
Potential: 30
Risk: 77
Updated: 2026-06-11 05:30
How recommendation works
Why AI thinks so:
Weak fundamentals and negative momentum raise significant concerns.
Track in portfolio
Price chart
AI recommendation
Analyst forecast
Calendar event
Positive signal
Negative signal
Neutral / update
Hold / informational
B My buy
S My sell
AI recommendation changes
| Date | Before | After | Reason |
|---|---|---|---|
| 2026-06-05 02:55 | Hold | Sell | Weak fundamentals and high risk limit upside potential. |
| 2026-05-28 02:35 | Sell | Hold | Weak fundamentals and high risk limit upside potential. |
| 2026-05-20 02:35 | Hold | Sell | scenario_deterioration |
Analyst forecasts
| Date | Analyst | Action | Target | Price Then |
|---|---|---|---|---|
| 2026-04-20 11:57 | Canaccord Genuity | Target Raised | 14 → 15 | 5.2 |
| 2026-03-27 08:52 | Deutsche Bank | Update | — → 12 | 3.35 |
| 2026-03-06 20:37 | Jefferies | Update | — → 10 | 3.39 |
Аналитики Oppenheimer ожидают роста акций компаний AtaiBeckley (ATAI), Compass Pathways (CMPS) и Definium Therapeutics (DFTX) после указа Трампа о психоделиках
Недавний указ президента Дональда Трампа о применении психоделических препаратов для лечения психических заболеваний может привести к росту акций компаний в этом секторе, согласно аналитикам Oppenheimer.
Аналитики Deutsche Bank начали покрытие компании Atai Life Sciences (ATAI), прогнозируя рост акций более чем на 250% с целевой ценой $12 на фоне популярности психоделических терапий
Deutsche Bank начал покрытие компании AtaiBeckley с рекомендацией 'покупать' и целевой ценой в $12, что предполагает более 250% роста от закрытия в пятницу.